Microbiota-Centered Interventions: The Next Breakthrough in Immuno-Oncology?

Area of Science:

• Immunology
• Microbiology
• Oncology

Background:

• The tumor microenvironment critically influences cancer-immune interactions and immunotherapy outcomes.
• The intestinal ecosystem plays a vital role in modulating anticancer immune responses and immunotherapy efficacy.
• Antibiotics can diminish the effectiveness of immune checkpoint inhibitors (ICI), while fecal microbial transplantation may re-sensitize patients to these therapies.

Purpose of the Study:

• To review the dual role of intestinal bacteria in the context of the intestinal barrier, metabolism, and immune responses during cancer treatment.
• To discuss diagnostic methods for identifying gut dysbiosis.
• To explore future microbiota-based therapeutic strategies in immuno-oncology.

Main Methods:

• Literature review focusing on the interplay between gut microbiota, the intestinal barrier, metabolism, and systemic immunity.
• Analysis of studies investigating the impact of antibiotics and fecal microbial transplantation on cancer immunotherapy.
• Discussion of diagnostic tools for gut dysbiosis and emerging microbiota-centered interventions.

Main Results:

• Evidence suggests antibiotics negatively affect immune checkpoint inhibitor (ICI) efficacy.
• Fecal microbial transplantation has shown potential in restoring ICI responsiveness in melanoma patients.
• The balance of beneficial and detrimental microbial species is crucial for therapeutic outcomes.

Conclusions:

• The gut microbiota is a key factor in cancer immunotherapy success.
• Understanding and manipulating the gut microbiome offers promising avenues for enhancing cancer treatment.
• Microbiota-centered interventions represent a significant future direction for immuno-oncology.